Actively Recruiting
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
Led by InSilico Medicine Hong Kong Limited · Updated on 2024-06-07
60
Participants Needed
2
Research Sites
148 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to study ISM8207 in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma. The primary objective is to evaluate the safety and tolerability of ISM8207 orally administered in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma
CONDITIONS
Official Title
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female participants aged 18 years or older
- Histologically confirmed advanced or metastatic solid tumors with disease progression after standard therapy, intolerance to standard therapy, or no standard therapy available
- Histologically confirmed B-cell lymphoma with at least one prior line of standard therapy and relapsed or refractory disease
- Measurable or evaluable lesions according to RECIST or Lugano 2014 criteria
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
- Life expectancy of at least 12 weeks as judged by the investigator
- Adequate organ function based on medical assessment
- Ability to provide signed informed consent and comply with study requirements
- Agreement to use effective contraception during treatment and for 90 days after last dose for females of childbearing potential and males
You will not qualify if you...
- Prior treatment with QPCTL, CD47, or SIRPα inhibitors
- Diagnosis of Burkitt lymphoma/leukemia, plasma cell myeloma, or plasmablastic lymphoma
- Participation in other therapeutic clinical studies within 28 days or 5 half-lives prior to first study dose
- Anti-tumor therapy within 28 days or 5 half-lives prior to first study dose
- Allogeneic or autologous stem cell transplantation within 3 months prior to study treatment
- Unresolved toxicity greater than Grade 1 from prior therapies (except alopecia)
- Antitumor steroid therapy within 7 days prior to first study dose
- Presence of serious illness or medical condition(s)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
2
Shanghai Jiao Tong University School of Medicine-Ruijin Hospital
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
Research Team
Y
Yichen Liu
CONTACT
J
Juan Xu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here